Concord Biotech Ltd Quarterly Results
Q1 FY26-27 Results Summary
Revenue
The revenue stands at ₹257.49 crore, reflecting a quarter-on-quarter *(QoQ) decrease of 21.03 per cent from ₹326.08 crore. This corresponds to a year-on-year *(YoY) growth of 26.23 per cent.
Operating Profit
Operating Profit stands at ₹82.38 crore, reflecting a quarter-on-quarter *(QoQ) decrease of 30.39 per cent from ₹118.35 crore. This corresponds to a year-on-year *(YoY) growth of 34.17 per cent.
PBDT
PBDT stands at ₹96.45 crore, reflecting a quarter-on-quarter *(QoQ) decrease of 27.82 per cent from ₹133.62 crore. This corresponds to a year-on-year *(YoY) growth of 26.05 per cent.
Profit Before Tax
Profit Before Tax stands at ₹78.35 crore, reflecting a quarter-on-quarter *(QoQ) decrease of 31.32 per cent from ₹114.08 crore. This corresponds to a year-on-year *(YoY) growth of 33.38 per cent.
Net Profit
Net Profit stands at ₹57.70 crore, reflecting a quarter-on-quarter *(QoQ) decrease of 34.78 per cent from ₹88.47 crore. This represents a 30.96 per cent year-on-year *(YoY) growth for the same year.
- YoY compares a quarter to the same period last year, and QoQ compares it to the previous quarter.
Concord Biotech Ltd News
Concord Biotech Ltd Earnings
- YOY
- QOQ
Concord Biotech Ltd Earning Charts
Revenue from Operations
in ₹ cr
EBITDA
in ₹ cr
Profit before Tax
in ₹ cr
Net Profit
in ₹ cr
Concord Biotech Ltd Research Reports
| Action | Target Price (₹) | Broker | Date | Reports |
|---|---|---|---|---|
| Data Not Found | ||||
Concord Biotech Ltd Financial Reports
Concord Biotech Ltd Stock Prices Compare with Peers
| Company | 1 Day | 1 Week | 1 month | 3 month | 6 month | 1 Year |
|---|---|---|---|---|---|---|
| Concord Biotech | 4.27% | 3.15% | 5.44% | 26.48% | 16.03% | -13.43% |
| Alembic Pharma | -1.04% | 0.60% | -1.16% | 6.85% | 4.08% | -13.28% |
| Shilpa Medicare | 6.32% | 11.96% | 28.13% | 84.40% | 149.80% | 84.86% |
| Jubilant Pharmo | 3.03% | 4.01% | -1.42% | -3.24% | 1.61% | -10.93% |
| Corona Remedies | 0.92% | -0.71% | 1.57% | 27.83% | 28.86% | 44.73% |
| Marksans Pharma | -0.66% | 0.55% | 0.93% | 36.96% | 44.76% | 45.61% |
| Viyash Scientific | -1.19% | 0.09% | -3.68% | 27.41% | 22.62% | 57.13% |
Company Info
Company Information
Chairman / Executive Director / M D / Promoter : SUDHIR JAIRAM VAID
ED / Joint MD / CEO / Promoter : ANKUR VAID
Non-Exec & Non-Independent Dir : Ravi Kapoor
Non-Exec & Non-Independent Dir : Rajiv Agarwal
Independent Non Exe. Director : BHARTI KHANNA
Independent Non Exe. Director : Amitabh Thakore
Independent Non Exe. Director : Arvind Agarwal
Independent Non Exe. Director : Jayaram Easwaran
Independent Non Exe. Director : Mandayam Chakravarthy Sriraman
Company Sec. & Compli. Officer : Paritosh Trivedi
Independent Non Exe. Director : EKTA GUPTA